RCS - Adv Medical Solutns. - Upcoming Investor Conferences

Advanced Medical Solutions

27/10/2025 07:00

RNS Number : 8152E

Advanced Medical Solutions Grp PLC

27 October 2025

 

27 October 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

AMS to participate in upcoming investor conferences in November and December

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), the innovative tissue healing medical device company delivering high-performing, cost-effective solutions for better patient outcomes, today announces that the Group will be participating in the following investor conferences in November and December:

·      Investec UK CEO Conference, London

Date: 11 November 2025

Format: One-on-one and group investor meetings

 

·      Berenberg European Conference, Windsor

Date: 4 December 2025

Format: One-on-one and group investor meetings

- End -

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc
Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Optimum Strategic Communications
Tel: +44 (0) 20 4566 8543
Mary Clark/ Nick Bastin / Isabelle Abdou
AMS@optimumcomms.com
Investec Bank PLC (NOMAD & Broker)
Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
Berenberg (Joint Broker)
Tel: +44 (0)20 3207 7800
Toby Flaux / Detlir Elezi


 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is an innovative tissue healing medical device company delivering high-performing, cost-effective solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.

AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear growth trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAEASELAFKSFFA